RT Journal Article
SR Electronic
T1 Autofluorescence Virtual Staining System for H&E Histology and Multiplex Immunofluorescence Applied to Immuno-Oncology Biomarkers in Lung Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.12.24308841
DO 10.1101/2024.06.12.24308841
A1 Loo, Jessica
A1 Robbins, Marc
A1 McNeil, Carson
A1 Yoshitake, Tadayuki
A1 Santori, Charles
A1 Shan, Chuanhe (Jay)
A1 Vyawahare, Saurabh
A1 Patel, Hardik
A1 Wang, Tzu Chien
A1 Findlater, Robert
A1 Steiner, David F.
A1 Rao, Sudha
A1 Gutierrez, Michael
A1 Wang, Yang
A1 Sanchez, Adrian C.
A1 Yin, Raymund
A1 Velez, Vanessa
A1 Sigman, Julia S.
A1 Coutinho de Souza, Patricia
A1 Chandrupatla, Hareesh
A1 Scott, Liam
A1 Weaver, Shamira S.
A1 Lee, Chung-Wein
A1 Rivlin, Ehud
A1 Goldenberg, Roman
A1 Couto, Suzana S.
A1 Cimermancic, Peter
A1 Wong, Pok Fai
YR 2024
UL http://medrxiv.org/content/early/2024/06/13/2024.06.12.24308841.abstract
AB Virtual staining for digital pathology has great potential to enable spatial biology research, improve efficiency and reliability in the clinical workflow, as well as conserve tissue samples in a non-destructive manner. In this study, we demonstrate the feasibility of generating virtual stains for hematoxylin and eosin (H&E) and a multiplex immunofluorescence (mIF) immuno-oncology panel (DAPI, PanCK, PD-L1, CD3, CD8) from autofluorescence images of unstained non-small cell lung cancer tissue by combining high-throughput hyperspectral fluorescence microscopy and machine learning. Using domain-specific computational methods, we evaluated the accuracy of virtual H&E for histologic subtyping and virtual mIF for cell segmentation-based measurements, including clinically-relevant measurements such as tumor area, T cell density, and PD-L1 expression (tumor proportion score and combined positive score). The virtual stains reproduce key morphologic features and protein biomarker expressions at both tissue and cell levels compared to real stains, enable the identification of key immune phenotypes important for immuno-oncology, and show moderate to good performance across various evaluation metrics. This study extends our previous work on virtual staining from autofluorescence in liver disease and prostate cancer, further demonstrating the generalizability of this deep learning technique to a different disease (lung cancer) and stain modality (mIF).Significance We extend the capabilities of virtual staining from autofluorescence to a different disease and stain modality. Our work includes newly developed virtual stains for H&E and a multiplex immunofluorescence panel (DAPI, PanCK, PD-L1, CD3, CD8) for non-small cell lung cancer, which reproduce the key features of real stains.Competing Interest StatementThis work was supported by Verily Life Sciences LLC and Genmab US, Inc. Verily Life Sciences LLC reports patent applications on virtual staining and alignment. JL, MR, CM, TY, CS, CJS, SV, HP, TCW, RF, SR, MG, YW, ACS, RY, VV, JSS, SSW, ER, RG, PC, and PFW are current or former employees with equity interests during tenure at Verily Life Sciences LLC. DFS is a current employee with equity interests at Google LLC. PCDS, HC, LS, CWL, and SSC are current or former employees at Genmab US, Inc. All authors performed work for this study during their respective tenures.Funding StatementThis work was supported by Verily Life Sciences LLC and Genmab US, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:WCG IRB waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDue to the nature of this research, data is not available.